TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33761182

Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration between registered nurses (RNs) and general practitioners (GPs)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Continuity of care provided by existing GPs for new residents
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Access to medication management systems
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Inclusion of family in the care team
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Informational continuity of care
Number of subjects: 35
Study: 35938229

Group type: EXPERIMENTAL
Intervention: NAFLD Fibrosis Index (NFI) model
Number of subjects: 309
Study: 34368187

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg intravenous)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg intravenous) during hypoxia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo during hypoxia
Number of subjects: 24
Study: 33046128

Group type: EXPERIMENTAL
Intervention: Decoction + Moxibustion (MD)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo + Moxibustion (MP)
Number of subjects: 462
Study: 34417198

Group type: EXPERIMENTAL
Intervention: tivozanib 1.34 mg orally once daily for 21 consecutive days of every 28‐day cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: sorafenib 400 mg orally twice daily continuously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tivozanib
Number of subjects: 0
Study: 33952544

Group type: EXPERIMENTAL
Intervention: Self-management (SM) intervention as part of a non-blinded block-randomised controlled trial (RCT) with assessments at T1, T2, T3, and T4.
Number of subjects: 526

Group type: COMPARATOR
Intervention: Control group receiving standard care without the SM intervention.
Number of subjects: 526
Study: 35659622

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 36250677

Group type: EXPERIMENTAL
Intervention: Machine learning model for blood pixel classification
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (low skill and novice surgeons)
Number of subjects: 3
Study: 33203433

Group type: EXPERIMENTAL
Intervention: Sexual health promotion intervention (3 individual sessions of 1 hour)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 72
Study: 33766814

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate (MPA) 400 mg intramuscularly on day 1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medroxyprogesterone Acetate (MPA) 400 mg intramuscularly on day 1 plus Entinostat 5 mg orally on days 1, 8, and 15
Number of subjects: 50
Study: 32543450

Group type: EXPERIMENTAL
Intervention: Smoking among university students
Number of subjects: 4599

Group type: EXPERIMENTAL
Intervention: Non-medical and non-health colleges
Number of subjects: 4599

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 4599
Study: 36154103

Group type: EXPERIMENTAL
Intervention: Dual therapy with statin and ezetimibe
Number of subjects: 2860

Group type: EXPERIMENTAL
Intervention: Statin monotherapy
Number of subjects: 2860

Group type: COMPARATOR
Intervention: Higher target group (LDL cholesterol of 100±10 mg/dL)
Number of subjects: 2860
Study: 36441246

Group type: EXPERIMENTAL
Intervention: Ronch®AP palatal device
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22
Study: 34425070

Group type: EXPERIMENTAL
Intervention: Awake prone positioning
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1126
Study: 32640956

Group type: EXPERIMENTAL
Intervention: Fenugreek vaginal cream 5% (0.5g, twice a week for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conjugated estrogens vaginal cream (0.625 mg, containing 0.3 mg of conjugated estrogens)
Number of subjects: 60
Study: 36088292

Group type: COMPARATOR
Intervention: 4 cycles of MATRix (control treatment)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Pre-phase (R/HD-MTX) followed by 2 cycles of MATRix (experimental treatment)
Number of subjects: 326
Study: 32639518

Group type: EXPERIMENTAL
Intervention: Evacetrapib, 130 mg/d
Number of subjects: 12092

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12092

Group type: EXPERIMENTAL
Intervention: Evacetrapib
Number of subjects: 12092
Study: 33711136

Group type: EXPERIMENTAL
Intervention: Closure of mesenteric defects with clips
Number of subjects: 401

Group type: COMPARATOR
Intervention: Non-closure of mesenteric defects
Number of subjects: 401

Group type: COMPARATOR
Intervention: Closure of mesenteric defects with clips and Non-closure of mesenteric defects
Number of subjects: 401
Study: 32804742

Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg daily added to ongoing antidepressant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 616926927

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg IV
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tramadol 1 mg/kg IV
Number of subjects: 50
Study: 34273258

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet of metformin hydrochloride/vildagliptin 850 mg/50 mg (test preparation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Branded product of metformin hydrochloride/vildagliptin 850 mg/50 mg (reference preparation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 30
Study: 33337821

Group type: EXPERIMENTAL
Intervention: NPTQ short form (NPTQ-SF)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: NPTQ
Number of subjects: 137

Group type: COMPARATOR
Intervention: NPTQ and NPTQ-SF
Number of subjects: 137
Study: 33346814

Group type: EXPERIMENTAL
Intervention: BoNT injection
Number of subjects: 30
Study: 33966115

Group type: EXPERIMENTAL
Intervention: Radiotherapy doses > 40 Gy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Radiotherapy doses > 50 Gy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Radiotherapy doses > 60 Gy
Number of subjects: 53
Study: 34715031

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (900 mg daily for 6 months)
Number of subjects: 985

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (in patients without asymptomatic gallstones)
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (in patients undergoing RYGB)
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 985
Study: 32087694

Group type: EXPERIMENTAL
Intervention: Progressive dual-task training with variable- to fixed-priority instructions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dual-task training with variable-priority attention exercises
Number of subjects: 60
Study: 34378087

Group type: EXPERIMENTAL
Intervention: CVnCoV 2μg
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: CVnCoV 4μg
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: CVnCoV 6μg
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: CVnCoV 8μg
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: CVnCoV 12μg
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 32320947

Group type: EXPERIMENTAL
Intervention: Simulated landing with various injury-risk profiles
Number of subjects: 35
Study: 37185165

Group type: EXPERIMENTAL
Intervention: Patient with comorbid depression
Number of subjects: 59
Study: 33256869

Group type: EXPERIMENTAL
Intervention: DASH diet (DG)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 49
Study: 35371366

Group type: EXPERIMENTAL
Intervention: Knee taping plus supervised exercise program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supervised exercise program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between groups A and B
Number of subjects: 40
Study: 33472432

Group type: EXPERIMENTAL
Intervention: Cluster randomized trial for school reopening
Number of subjects: 0
Study: 35710085

Group type: EXPERIMENTAL
Intervention: Interactive pretest webtool
Number of subjects: 346

Group type: COMPARATOR
Intervention: Germline counseling
Number of subjects: 346
Study: 33383492

Group type: EXPERIMENTAL
Intervention: CCAT + tDCS
Number of subjects: 75

Group type: COMPARATOR
Intervention: CCAT + sham tDCS
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 32162804

Group type: EXPERIMENTAL
Intervention: vanucizumab 2,000 mg plus mFOLFOX-6
Number of subjects: 189

Group type: COMPARATOR
Intervention: bevacizumab 5 mg/kg plus mFOLFOX-6
Number of subjects: 189
Study: 35445567

Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel (up to 12 mg/day)
Number of subjects: 138
Study: 33846498

Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 antagonist)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Dexamethasone (corticosteroid)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (control group in Trial B)
Number of subjects: 140
Study: 35532299

Group type: EXPERIMENTAL
Intervention: Malarone® with ketoconazole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Malarone® alone
Number of subjects: 10
Study: 32175655

Group type: COMPARATOR
Intervention: Efpeglenatide (2-100 μg/kg single dose)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Efpeglenatide (1, 2, or 4 mg once weekly for 8 weeks; 8, 12, or 16 mg once monthly for 9 weeks)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Efpeglenatide (various doses)
Number of subjects: 119
Study: 33038014

Group type: EXPERIMENTAL
Intervention: Dengue serology testing
Number of subjects: 4948
Study: 35489112

Group type: EXPERIMENTAL
Intervention: Mini-flipped, game-based Mediterranean diet learning program (8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34573983

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 1254

Group type: COMPARATOR
Intervention: MX+US
Number of subjects: 1254
Study: 35268154

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 0.5% (R0.5%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg kg−1 plus ropivacaine 0.5% (MR0.5%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg kg−1 plus ropivacaine 0.35% (MR0.35%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg kg−1 plus ropivacaine 0.25% (MR0.25%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 50
Study: 34768274

Group type: EXPERIMENTAL
Intervention: Heated hatha yoga (HY)
Number of subjects: 1
Study: 32960654

Group type: EXPERIMENTAL
Intervention: ICD-10 code for alcohol-related cirrhosis (K70.3)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: ICD-10 code for unspecified cirrhosis (K74.6)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: ICD-10 code for oesophageal varices (I85.0/I85.9)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: ICD-10 code for hepatocellular carcinoma (HCC, C22.0)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: ICD-10 code for liver-related ascites (R18.9)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Combination of ascites code with a code for chronic liver disease
Number of subjects: 750
Study: 33973407

Group type: EXPERIMENTAL
Intervention: Nurse-led consultations
Number of subjects: 280

Group type: COMPARATOR
Intervention: Rheumatologist follow-up visits
Number of subjects: 280
Study: 34243752

Group type: EXPERIMENTAL
Intervention: Economic support in the form of Social Cash Transfers (SCTs) and payment of school fees
Number of subjects: 48
Study: 32159722

Group type: EXPERIMENTAL
Intervention: Confirmed acute ischemic infarct
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Stroke mimics
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Normal imaging
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Elderly patients with atrial fibrillation, arterial hypertension, dysarthria, or right motor impairment
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Female patients with low vascular risk factors, low NIHSS, decreased level of consciousness, or symptoms suggestive of posterior circulation
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Overall patients seen at the stroke unit
Number of subjects: 736
Study: 37578599

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced computed tomography (CECT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-contrast computed tomography (NCCT)
Number of subjects: 105
Study: 32107571

Group type: EXPERIMENTAL
Intervention: D2/D3 dopamine agonist (pramipexole)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 33856733

Group type: EXPERIMENTAL
Intervention: Crocin (15 mg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 32222135

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg twice daily) plus aspirin
Number of subjects: 6564

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 6564
Study: 35550342

Group type: EXPERIMENTAL
Intervention: Femoral, sciatic and obturator nerve blocks (group FSO) [n = 50; ropivacaine 0.75% (0.75 mg kg–1)]
Number of subjects: 88

Group type: COMPARATOR
Intervention: Femoral, sciatic and placebo (group FSP) [n = 50; ropivacaine 0.75% (0.75 mg kg–1) and saline solution 0.9% (0.1 mL kg–1)]
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups (FSO and FSP)
Number of subjects: 88
Study: 33572650

Group type: EXPERIMENTAL
Intervention: Eco-Bio-Social (EBS) strategy including environmental management, introduction of beta fish, elimination of breeding sites, mobilization and training of community members, and community surveillance of arboviruses.
Number of subjects: 16000

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 16000
Study: 35879610

Group type: EXPERIMENTAL
Intervention: Urate-lowering therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial flares
Number of subjects: 0
Study: 34592164

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg once a day for 24 weeks) + ivGCs (methylprednisolone 500 mg once a week for 6 weeks followed by 250 mg once a week for an additional six weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: ivGCs (methylprednisolone 500 mg once a week for 6 weeks followed by 250 mg once a week for an additional six weeks)
Number of subjects: 88
Study: 35704092

Group type: EXPERIMENTAL
Intervention: Single-stapling techniques (SST)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Double-stapling technique (DST)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Overall morbidity and mortality
Number of subjects: 272
Study: 34297336

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia using automated servo-controlled cooling devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (normothermia)
Number of subjects: 0
Study: 32070323

Group type: EXPERIMENTAL
Intervention: Vitamin D vaginal suppository (1000 units of vitamin D3)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo vaginal suppository
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 105
Study: 35051686

Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 1433
Study: 33483132

Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.5 μg kg‐1 min‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phenylephrine (30-50 μg kg‐1 min‐1) in mice
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline in mice
Number of subjects: 20
Study: 34563273

Group type: EXPERIMENTAL
Intervention: Adjuvant atezolizumab after adjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32331005

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (56 mg or 84 mg) in combination with newly initiated oral antidepressant (ESK+AD)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Oral antidepressant + placebo nasal spray (AD+PBO)
Number of subjects: 223
Study: 35326659

Group type: EXPERIMENTAL
Intervention: Topical bimiralisib 2.0% gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 33957642

Group type: EXPERIMENTAL
Intervention: Fractionated CO2 laser
Number of subjects: 52

Group type: COMPARATOR
Intervention: Topical clobetasol propionate
Number of subjects: 52
Study: 32797473

Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg/2 weeks intramuscularly)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35168477

Group type: EXPERIMENTAL
Intervention: Various treatment approaches
Number of subjects: 8
Study: 34328024

Group type: EXPERIMENTAL
Intervention: Home-based electrical stimulation (E-Stim) therapy for 1 hour daily for 4 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group with an identical but non-functional device for 4 weeks
Number of subjects: 33
Study: 32579785

Group type: EXPERIMENTAL
Intervention: MA formulation (3.75 μg HA + AS03 adjuvant system)
Number of subjects: 617

Group type: COMPARATOR
Intervention: MB formulation (3.75 μg HA + 1/2AS03)
Number of subjects: 617

Group type: COMPARATOR
Intervention: HA formulation (7.5 μg HA + AS03)
Number of subjects: 617

Group type: COMPARATOR
Intervention: HB formulation (7.5 μg HA + 1/2AS03)
Number of subjects: 617
Study: 33892684

Group type: EXPERIMENTAL
Intervention: Rumination-focused cognitive behavioral therapy (RFCBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RFCBT
Number of subjects: 0
Study: 33622643

Group type: EXPERIMENTAL
Intervention: Informative story book read at least once before surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-medical, colorful story book
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Informative story book read ≥3 times
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mothers with low education level
Number of subjects: 120
Study: 32149537

Group type: EXPERIMENTAL
Intervention: Pure tone air conduction audiometry (frequencies 0.125‐8.0 kHz)
Number of subjects: 72
Study: 36244853

Group type: EXPERIMENTAL
Intervention: Educational interventional program involving motivational interviewing
Number of subjects: 268

Group type: COMPARATOR
Intervention: Standard medication counseling
Number of subjects: 268
Study: 34498222

Group type: EXPERIMENTAL
Intervention: Cisgender gay men in Canada
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Fa'afafine in Samoa
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Masculine muxe nguiiu in Istmo Zapotec
Number of subjects: 3

Group type: COMPARATOR
Intervention: Feminine muxe gunaa in Istmo Zapotec
Number of subjects: 3
Study: 36347946

Group type: EXPERIMENTAL
Intervention: 20 dS m‐1 + Water Stress (WS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 dS m‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 32253389

Group type: EXPERIMENTAL
Intervention: Adhesive restorative system (Single Bond Universal/Z350XT) with selective enamel conditioning
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adhesive restorative system (Single Bond Universal/Z350XT) without selective enamel conditioning
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resin‐modified glass‐ionomer cement (Vitremer) with EDTA pretreatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resin‐modified glass‐ionomer cement (Vitremer) without EDTA pretreatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 50
Study: 35420682

Group type: EXPERIMENTAL
Intervention: Weight loss (median: -0.23 kg/m2 per year)
Number of subjects: 5985

Group type: EXPERIMENTAL
Intervention: Weight loss assessed approximately 14 to 18 years preceding dementia diagnosis
Number of subjects: 5985
Study: 33691142

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 158

Group type: COMPARATOR
Intervention: Audiobooks (control)
Number of subjects: 158
Study: 32955567

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36058950

Group type: EXPERIMENTAL
Intervention: Intratesticular (IT) administration of 10 mg/kg ZT
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intramuscular (IM) administration of 10 mg/kg ZT
Number of subjects: 14
Study: 34932104

Group type: EXPERIMENTAL
Intervention: Integrated care supported by mHealth technology (ABC pathway)
Number of subjects: 1890

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1890
Study: 36113117

Group type: EXPERIMENTAL
Intervention: Gaze and postural stability (GPS) retraining intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Strength and endurance (SAE) intervention
Number of subjects: 41
Study: 34103426

Group type: EXPERIMENTAL
Intervention: Modulated sinusoidal currents electrophoresis of the phytocomplex
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ultraphonophoresis of the phytocomplex
Number of subjects: 72

Group type: COMPARATOR
Intervention: Amplipulse therapy (modulated sinusoidal currents)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ultrasound therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Basic drug therapy
Number of subjects: 72
Study: 33467603

Group type: EXPERIMENTAL
Intervention: Global postural re-education (GPR) therapy session (10 min session)
Number of subjects: 8
Study: 32059684

Group type: EXPERIMENTAL
Intervention: Financial voucher incentives (up to £400) added to usual Stop Smoking Services (SSS) support
Number of subjects: 940

Group type: COMPARATOR
Intervention: Usual Stop Smoking Services (SSS) support alone
Number of subjects: 940
Study: 35773492

Group type: EXPERIMENTAL
Intervention: Patients with anastomotic leaks (AL)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Patients without anastomotic leaks (AL)
Number of subjects: 311
Study: 34036613

Group type: EXPERIMENTAL
Intervention: Community-based monitoring by trained optometrists
Number of subjects: 38

Group type: COMPARATOR
Intervention: Hospital-based care
Number of subjects: 38
Study: 32181922

Group type: EXPERIMENTAL
Intervention: Deep Learning Algorithm (YOLOv3)
Number of subjects: 50

Group type: COMPARATOR
Intervention: POCUS Experts
Number of subjects: 50

Group type: COMPARATOR
Intervention: POCUS Expert 1
Number of subjects: 50
Study: 36003983

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Low-intensity active video gaming (AVG)
Number of subjects: 82